FibroGen, Inc.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. Show More...

  • Website http://www.fibrogen.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.29 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -0.69 -0.32 -3.17 -1.42 -0.93 -1.66 -1.03 -0.89 -1.25
    Dividends USD
    Payout Ratio % *
    Shares Mil 47.0 47.0 19.0 60.0 63.0 73.0 84.0 87.0 87.0
    Book Value Per Share * USD -3.78 3.51 2.8 6.93 5.52 6.78 5.14
    Free Cash Flow Per Share * USD 0.24 -0.12 -0.24 -1.3 -0.82 -0.65
    Return on Assets % -12.26 -5.31 -15.25 -17.98 -13.12 -18.45 -9.71 -8.86 -13.43
    Financial Leverage (Average) 2.18 2.65 3.01 1.6 1.73 1.66 1.8
    Return on Equity % -43.0 -37.0 -35.1 -16.12 -15.01 -23.2
    Return on Invested Capital % -26.28 -20.31 -26.9 -13.7 -15.12 -22.51
    Interest Coverage -2.26 -0.4 -4.36 -6.75 -4.76 -11.97 -6.84 -25.65 -39.07
    Current Ratio 2.23 3.83 3.15 2.99 4.09 9.69 7.75 6.84 11.14
    Quick Ratio 2.06 3.74 3.08 2.93 4.05 9.63 7.69 5.47 8.99
    Debt/Equity 0.44 0.55 0.62 0.17 0.19 0.07 0.08